SCHEMBL22490902

SCHEMBL22490902

O=C(OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.52
CHRNA5 P30532 1/20 0.52
CHRNA7 P36544 1/20 0.52
CHRNA4 P43681 1/20 0.52
PARP10 Q53GL7 2/20 0.51
NR4A1 P22736 1/20 0.50
NR4A2 P43354 1/20 0.50
NR4A3 Q92570 1/20 0.50
MAOB P27338 1/20 0.48
SRD5A2 P31213 1/20 0.47
ADRB2 P07550 1/20 0.46
ADRB1 P08588 1/20 0.46
ADRB3 P13945 1/20 0.46
PLA2G4B P0C869 1/20 0.45
LMNA P02545 1/20 0.44
SLC6A2 P23975 1/20 0.43
SLC6A3 Q01959 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23488173 0.89 CHRNB2 (0.53) CHRNB2CHRNA5CHRNA7CHRNA4PARP10
SCHEMBL23488604 0.89 CHRNB2 (0.53) CHRNB2CHRNA5CHRNA7CHRNA4PARP10
SCHEMBL22490932 0.88 CHRNB2 (0.50) CHRNB2CHRNA5CHRNA7CHRNA4PARP10
SCHEMBL22490872 0.88 CHRNB2 (0.50) CHRNB2CHRNA5CHRNA7CHRNA4PARP10
SCHEMBL22490912 0.88 CHRNB2 (0.50) CHRNB2CHRNA5CHRNA7CHRNA4PARP10
SCHEMBL23488128 0.87 CHRNB2 (0.51) CHRNB2CHRNA5CHRNA7CHRNA4PARP10
SCHEMBL23488668 0.87 CHRNB2 (0.51) CHRNB2CHRNA5CHRNA7CHRNA4PARP10
SCHEMBL23488262 0.87 CHRNB2 (0.51) CHRNB2CHRNA5CHRNA7CHRNA4PARP10
SCHEMBL22490879 0.86 CHRNB2 (0.48) CHRNB2CHRNA5CHRNA7CHRNA4PARP10
SCHEMBL21112887 0.85 SMN1; SMN2 (0.50) PARP10MAOBSRD5A2TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-06-10 US disclosed
EP-3717463-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN Sanofi (FR) 2020-10-07 EP disclosed
CN-111433193-A Novel conjugates of agents and moieties capable of binding to glucose sensing proteins 赛诺菲 2020-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210170033-A1 NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 CHRNB2 3085/4885CHRNA5 3785/4885CHRNA7 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.